A Phase 3 interventional study of Dupilumab and Matching Placebo in Dermatitis, Atopic, sponsored by Regeneron Pharmaceuticals. Completed at 61 sites in 6 countries. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2020-08-13.
Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing dupilumab in Dermatitis, Atopic — 4 open to participants now, 6 under way, none of them phase 3. dupilumab · Dermatitis, Atopic.
Among the 50 studies testing dupilumab in Dermatitis, Atopic, this one is the 9th largest by enrollment, is one of 4 that started in 2017, is one of 11 in phase 3, and was the 20th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →4 of the 50 studies testing dupilumab in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:
Northwestern University · Sites in United States
Ages 6–17
University of California, San Francisco · Sites in United States
Ages 18+
University of Michigan · Sites in United States
Ages 18+
Sanofi
Ages 18+
By country, each count listing its studies:
dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 6 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, dupilumab is the treatment under test here. Read study by study →
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 12 · Phase 4 24
First in 2011; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 367 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 75 across the 50 interventional studies. Of the 38 that completed or were terminated, 26 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 50 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
30 studies in Dermatitis, Atopic by Regeneron Pharmaceuticals: 1 open now, 2 under way, none of them phase 3. Of 27 finished, 18 (67%) have results posted.
Among the 30 studies in Dermatitis, Atopic by Regeneron Pharmaceuticals, this one is the 8th largest by enrollment of the 25 interventional ones that give a count, is one of 4 that started in 2017, is one of 9 in phase 3, and was the 20th registered.
Regeneron Pharmaceuticals’s Dermatitis, Atopic studies by the year they started, since 2011.
4 of the studies testing dupilumab in Dermatitis, Atopic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07905547SanofiA Study to Investigate Dupixent/ Dupilumab in Adult Indian Participants With Moderate-to-severe Atopic Dermatitis | 2027-02-07 |
| NCT05983068SanofiA Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis | 2027-04-29 |
| NCT05042258Northwestern UniversityUsing Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis | 2027-06 |
| NCT05268107University of MichiganEthnic Differences in Mechanisms of Action of Dupilumab | 2027-07 |
Add all 4 to your calendar (.ics) → With an account.
Among the 50 studies testing dupilumab in Dermatitis, Atopic, from their registry updates:
Among Regeneron Pharmaceuticals’s 30 in Dermatitis, Atopic:
This tab as a report to print or save as PDF → With an account.
The main objective of the trial is to demonstrate the efficacy of dupilumab administered concomitantly with topical corticosteroids (TCS) in participants ≥6 years to \<12 years of age with severe atopic dermatitis (AD).
The secondary objective is to assess the safety of dupilumab administered concomitantly with TCS in patients ≥6 years to \<12 years of age with severe AD.
Key Inclusion Criteria:
Key Exclusion Criteria:
Having used any of the following treatments within 4 weeks before the baseline visit, or any condition that, in the opinion of the investigator, is likely to require such treatment(s) during the first 4 weeks of study treatment:
Treatment with biologics, as follows:
Any cell-depleting agents including but not limited to rituximab:
within 6 months before the baseline visit, or until lymphocyte and CD 19+ lymphocyte count returns to normal, whichever is longer
Note: Other Inclusion/ Exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive dupilumab, dosing regimen 1
Drug: Dupilumab · Other: Background Treatment: Topical Corticosteroids · Other: Background Treatment: Moisturizers
Participants will receive dupilumab, dosing regimen 2
Drug: Dupilumab · Other: Background Treatment: Topical Corticosteroids · Other: Background Treatment: Moisturizers
Participants will receive matching placebo
Drug: Matching Placebo · Other: Background Treatment: Topical Corticosteroids · Other: Background Treatment: Moisturizers
Pharmaceutical form: Solution for injection in pre-filled syringe; Route of administration: Subcutaneous (SC)
Also known as: DUPIXENT®, REGN668, SAR231893
Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous (SC)
All participants are required to initiate treatment with a medium potency TCS using a standardized regimen. It is recommended that participants use triamcinolone acetonide 0.1% cream, fluocinolone acetonide 0.025% cream, or clobetasone butyrate 0.05%.
All participants should apply moisturizers throughout the study. All types of moisturizers are permitted, but participants may not initiate treatment with prescription moisturizers. Participants may continue using stable doses of such moisturizers if initiated before the screening visit.
Percentage of Participants With Investigator's Global Assessment (IGA) 0 or 1 at Week 16
The IGA was an assessment instrument used in clinical studies to rate the severity of AD globally, based on a 5-point scale ranging from 0 (clear) to 4 (severe). The full analysis set (FAS) included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized). Values after first rescue treatment used were set to missing. Participants with missing score at Week 16 were considered as a non-responder.
Time frame: Week 16
Percentage of Participants With Eczema Area and Severity Index -75 (EASI-75) (≥ 75 Percent (%) Improvement From Baseline) at Week 16
The EASI assesses severity and extent of atopic dermatitis (AD). Scores range from 0-72. Four AD disease characteristics (erythema, thickness, scratching, and lichenification) were assessed for severity on a scale of "0" (absent) through "3" (severe). Area of involvement assessed as a percentage by body area of head, trunk, upper limbs, and lower limbs, and converted to a score of 0 to 6. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized). Values after first rescue treatment used were set to missing. Participants with missing score at week 16 were considered as a non-responder.
Time frame: Week 16
Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 16
The EASI assesses severity and extent of AD. Scores range from 0-72. Four AD disease characteristics (erythema, thickness, scratching, and lichenification) were assessed for severity on a scale of "0" (absent) through "3" (severe). Area of involvement assessed as a percentage by body area of head, trunk, upper limbs, and lower limbs, and converted to a score of 0 to 6. FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized).
Time frame: Baseline (Day 1), Week 16
Percent Change From Baseline in Weekly Average of Daily Worst Itch Score at Week 16
The worst itch scale was a simple assessment tool that participants used to report the intensity of their pruritus (itch). This was an 11-point scale (0 to 10) in which 0 indicated no itching while 10 indicated worst itching possible. Participants were asked to answer 2 questions daily throughout the entire study (screening period, treatment period, and follow-up period). The daily worst itch score was calculated as the worse of the scores for the 2 questions. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized).
Time frame: Baseline (Day 1), Week 16
Percentage of Participants With Improvement (Reduction From Baseline) of Weekly Average of Daily Worst Itch Score ≥3 Points at Week 16
The worst itch scale was a simple assessment tool that participants used to report the intensity of their pruritus (itch). This was an 11-point scale (0 to 10) in which 0 indicated no itching while 10 indicated worst itching possible. Participants were asked to answer 2 questions daily throughout the entire study (screening period, treatment period, and follow-up period). The daily worst itch score was calculated as the worse of the scores for the 2 questions. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized). Values after first rescue treatment used were set to missing. Participants with missing score at week 16 were considered as a non-responder. Here "Number of participants analyzed" = number of participants who were evaluated for this specific endpoint.
Time frame: Week 16
Percentage of Participants With Improvement (Reduction From Baseline) of Weekly Average of Daily Worst Itch Score ≥4 Points at Week 16
The worst itch scale was a simple assessment tool that participants used to report the intensity of their pruritus (itch). This was an 11-point scale (0 to 10) in which 0 indicated no itching while 10 indicated worst itching possible. Participants were asked to answer 2 questions daily throughout the entire study (screening period, treatment period, and follow-up period). The daily worst itch score was calculated as the worse of the scores for the 2 questions. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized). Values after first rescue treatment used were set to missing. Participants with missing score at week 16 were considered as a non-responder. Here "Number of participants analyzed" = number of participants who were evaluated for this specific endpoint.
Time frame: Week 16
Percentage of Participants Achieving Eczema Area and Severity Index - 50 (EASI-50) (≥ 50% Improvement From Baseline) at Week 16
The EASI assessed severity and extent of AD. Scores range from 0-72. Four AD disease characteristics (erythema, thickness, scratching, and lichenification) were assessed for severity on a scale of "0" (absent) through "3" (severe). Area of involvement assessed as a percentage by body area of head, trunk, upper limbs, and lower limbs, and converted to a score of 0 to 6. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized). Values after first rescue treatment used were set to missing. Participants with missing score at week 16 were considered as a non-responder.
Time frame: Week 16
Percentage of Participants Achieving Eczema Area and Severity Index - 90 (EASI - 90) (≥ 90% Improvement From Baseline) at Week 16
The EASI assessed the severity and extent of atopic dermatitis (AD). Scores range from 0-72. Four AD disease characteristics (erythema, thickness, scratching, and lichenification) were assessed for severity on a scale of "0" (absent) through "3" (severe). Area of involvement assessed as a percentage by body area of head, trunk, upper limbs, and lower limbs, and converted to a score of 0 to 6. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized). Values after first rescue treatment used were set to missing. Participants with missing score at week 16 were considered as a non-responder.
Time frame: Week 16
Time to Achieve ≥ 4 Point Reduction of Weekly Average of Daily Worst Itch Score From Baseline During the 16-week Treatment Period
The worst itch scale: simple assessment tool that participants used to report intensity of their pruritus (itch). This was an 11-point scale (0 to 10) where 0 (no itching) and 10 (worst itching) possible. Participants were asked to answer 2 questions daily throughout the entire study (screening period, treatment period, \& follow-up period). The daily worst itch score was calculated as worse of scores for 2 questions. FAS was used. Time to event is calculated in weeks as (date of first event - date of first dose)/7. The event of NRS reduction ≥ 4 was based on observed data without setting data to be non-responder after rescue treatment use. Here "Number of participants analyzed" = number of participants who were evaluated for this specific endpoint \& "NA" represents "Not computable" as only 12.3% of participants achieved NRS reduction during 16-week treatment period \& hence median time to achieve ≥ 4-point reduction of NRS for placebo +TCS treated participants could not be reported.
Time frame: Baseline (Day 1) up to Week 16
Time to Achieve ≥ 3 Point Reduction of Weekly Average of Daily Worst Itch Score From Baseline During the 16-week Treatment Period
The worst itch scale: a simple assessment tool that participants used to report intensity of their pruritus (itch). This was an 11-point scale (0 to 10) where 0 (no itching) \& 10 (worst itching) possible. Participants were asked to answer 2 questions daily throughout the entire study (screening period, treatment period, \& follow-up period). Daily worst itch score was calculated as worse of scores for 2 questions. FAS was used. Time to event is calculated in weeks as (date of first event - date of first dose)/7. The event of NRS reduction ≥ 3 was based on observed data without setting data to be non-responder after rescue treatment use. Here "Number of participants analyzed" = number of participants who were evaluated for this specific endpoint \& "NA" represents "Not computable" as only 21.1% of participants achieved NRS reduction during 16-week treatment period \& hence median time to achieve ≥ 3-point reduction of NRS for placebo +TCS treated participants could not be reported.
Time frame: Baseline (Day 1) up to Week 16
Change From Baseline in Percent Body Surface Area (BSA) Affected by Atopic Dermatitis (AD) at Week 16
BSA affected by AD was assessed for each section of the body using the rule of nines (the possible highest score for each region is: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]) and were reported as a percentage of all major body sections combined. The proportion assigned to different body regions were different in younger children as compared to older children (head and neck area is assigned a higher proportion in younger children as compared to older children). The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized).
Time frame: Baseline (Day 1), Week 16
Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) at Week 16
SCORAD was used to assess the extent and severity of AD. Extent and severity of eczema as well as subjective symptoms (insomnia, etc) were assessed and scored. SCORAD total score ranges from 0 (absent disease) to 103 (severe disease). The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized).
Time frame: Baseline (Day 1), Week 16
Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) at Week 16
CDLQI was a validated 10 question tool to measure the impact of skin disease on the quality of life (QOL) in children by assessing how much the skin problem has affected the participant over the past week. Nine questions were scored as follows: Very much = 3, Quite a lot = 2, Only a little = 1, Not at all or unanswered = 0. Question 7 has an added possible response, which was scored as 3. CDLQI equals the sum of the score of each question (maximum = 30, minimum = 0). Higher the score, the greater the impact on QOL. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized). Data presented reflects the mean \& standard deviation of the CDLQI total scores.
Time frame: Baseline (Day 1), Week 16
Change From Baseline in Patient Oriented Eczema Measure (POEM) at Week 16
POEM was a 7-item, validated questionnaire used to assess disease symptoms in children and adults. The format was a response to 7 items (dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping) based on frequency of these disease symptoms during the past week (ie, 0 = no days, 1 = 1 to 2 days, 2 = 3 to 4 days, 3 = 5 to 6 days, and 4 = all days) with a scoring system of 0 to 28; the total score reflected the disease-related morbidity. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized). A high score is indicative of a poor quality of life.
Time frame: Baseline (Day 1), Week 16
Change From Baseline in Weekly Average of Daily Worst Itch Score at Week 16
The worst itch scale was a simple assessment tool that participants used to report the intensity of their pruritus (itch). This was an 11-point scale (0 to 10) in which 0 indicated no itching while 10 indicated worst itching possible. Participants were asked to answer 2 questions daily throughout the entire study (screening period, treatment period, and follow-up period). The daily worst itch score was calculated as the worse of the scores for the 2 questions. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized).
Time frame: Baseline (Day 1), Week 16
Change From Baseline in Dermatitis Family Index (DFI) at Week 16
DFI was a 10-item questionnaire with items inquiring about housework, food preparation, sleep, family leisure activity, shopping, expenditure, tiredness, emotional distress, relationships and the impact of helping with treatment on the primary caregiver's life. The DFI questions were scored on a four-point Likert scale ranging from 0 to 3, so that the total DFI score ranges from 0 to 30. Timeframe of reference was the past week. A higher DFI score indicated greater impairment in family Quality of life (QOL) as affected by atopic dermatitis. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized).
Time frame: Baseline (Day 1) , Week 16
Change From Baseline in Patient Reported Outcomes Measurements Information Systems (PROMIS) Pediatric Anxiety Short Form Scale Total Score at Week 16
PROMIS Anxiety instrument measures self-reported fear (fearfulness, panic), anxious misery (worry, dread), hyperarousal (tension, nervousness, restlessness), \& somatic symptoms related to arousal (racing heart, dizziness). Each question has 5 response options ranging in value from 1-5 (1=Never, 2=Almost never, 3=Sometimes, 4=Often, 5=Almost Always). Total raw score calculated using sum of response values: for 8-item form, lowest possible is 8 \& highest possible is 40; For 6-item form: lowest possible is 6; highest possible is 30. Higher score indicates greater severity of symptoms.
Time frame: Baseline (Day 1), Week 16
Change From Baseline in Patient Reported Outcomes Measurements Information Systems (PROMIS) Pediatric Depressive Symptoms Short Form Scale Score at Week 16
PROMIS Depression instrument assesses self-reported negative mood (sadness/guilt), views of self (self-criticism/worthlessness) \& social cognition (loneliness/interpersonal alienation), \& decreased positive affect \& engagement (loss of interest/meaning/purpose). Each question has 5 response options with values from 1-5 (1=Never, 2=Almost never, 3=Sometimes, 4=Often, 5=Almost Always). Total raw score is the sum of response values. For 8-item form, lowest possible is 8, highest is 40; for 6-item form, lowest possible is 6, highest is 30. Higher score indicates greater severity of symptoms.
Time frame: Baseline (Day 1), Week 16
Percentage of Participants Having at Least One Skin Infection Treatment Emergent Adverse Event (TEAE) (Excluding Herpetic Infections) Through Week 16
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) that developed or worsened or became serious during on-treatment period (time from the first dose of study drug up to the end of study. A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-subjects hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs. Percentage of participants having at least one skin infection TEAE (Excluding Herpetic Infections) through Week 16 were reported. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized).
Time frame: Baseline through Week 16
Percentage of Participants Having at Least One Serious Treatment Emergent Adverse Event (TEAE) Through Week 16
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) that developed or worsened or became serious during on-treatment period (time from the first dose of study drug up to the end of study. A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-participants hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized).
Time frame: Baseline (Day 1) through Week 16
Proportion of Topical Corticosteroid (TCS) Medication-free Days From Baseline to Week 16
Proportion of TCS medication-free days is calculated as the number of days that a participant used neither TCS/TCI nor system rescue therapy divided by the study days of each period. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized). Here "Number of participants analyzed" = number of participants who were evaluated for this specific endpoint.
Time frame: Baseline (Day 1), Week 16
Mean Weekly Dose of Topical Corticosteroid (TCS) in Grams for Low or Medium Potency TCS From Baseline to Week 16
Mean weekly dose of TCS in grams for low or medium potency TCS from baseline to Week 16 were reported. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized). Here "Number of participants analyzed" = number of participants who were evaluated for this specific endpoint.
Time frame: Baseline (Day 1), Week 16
A total of 474 participants were screened for study eligibility at multiple sites in the United States and Europe. Screen failure was mostly due to inclusion/exclusion criteria not met and "other" reasons. The majority of participants (221/367) were enrolled at study sites in the United States.
| Milestone | Placebo + TCS | Dupilumab 300 mg Q4W + TCS | Dupilumab 100 mg or 200 mg Q2W + TCS |
|---|---|---|---|
| Started | 123 | 122 | 122 |
| Completed week 16 study treatment | 114 | 118 | 119 |
| Completed week 28 end of study | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 |
| Not completed | 123 | 122 | 122 |
| Withdrew: Transition to another study at week 16 | 80 | 86 | 78 |
| Withdrew: Transition to ole during follow-up | 37 | 33 | 39 |
| Withdrew: Physician decision | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 5 | 1 | 2 |
| Withdrew: Other | 1 | 1 | 1 |
| Withdrew: Ongoing | 0 | 0 | 1 |
The IGA was an assessment instrument used in clinical studies to rate the severity of AD globally, based on a 5-point scale ranging from 0 (clear) to 4 (severe). The full analysis set (FAS) included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized). Values after first rescue treatment used were set to missing. Participants with missing score at Week 16 were considered as a non-responder.
| Percentage of Participants | Placebo + TCS | Dupilumab 300 mg Q4W + TCS | Dupilumab 100 mg or 200 mg Q2W + TCS |
|---|---|---|---|
| Percentage of Participants With Investigator's Global Assessment (IGA) 0 or 1 at Week 16 | 11.4 | 32.8 | 29.5 |
The EASI assesses severity and extent of atopic dermatitis (AD). Scores range from 0-72. Four AD disease characteristics (erythema, thickness, scratching, and lichenification) were assessed for severity on a scale of "0" (absent) through "3" (severe). Area of involvement assessed as a percentage by body area of head, trunk, upper limbs, and lower limbs, and converted to a score of 0 to 6. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized). Values after first rescue treatment used were set to missing. Participants with missing score at week 16 were considered as a non-responder.
| Percentage of Participants | Placebo + TCS | Dupilumab 300 mg Q4W + TCS | Dupilumab 100 mg or 200 mg Q2W + TCS |
|---|---|---|---|
| Percentage of Participants With Eczema Area and Severity Index -75 (EASI-75) (≥ 75 Percent (%) Improvement From Baseline) at Week 16 | 26.8 | 69.7 | 67.2 |
The EASI assesses severity and extent of AD. Scores range from 0-72. Four AD disease characteristics (erythema, thickness, scratching, and lichenification) were assessed for severity on a scale of "0" (absent) through "3" (severe). Area of involvement assessed as a percentage by body area of head, trunk, upper limbs, and lower limbs, and converted to a score of 0 to 6. FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized).
| Percent change | Placebo + TCS | Dupilumab 300 mg Q4W + TCS | Dupilumab 100 mg or 200 mg Q2W + TCS |
|---|---|---|---|
| Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 16 | -48.6 ± 2.46 | -82.1 ± 2.37 | -78.4 ± 2.35 |
The worst itch scale was a simple assessment tool that participants used to report the intensity of their pruritus (itch). This was an 11-point scale (0 to 10) in which 0 indicated no itching while 10 indicated worst itching possible. Participants were asked to answer 2 questions daily throughout the entire study (screening period, treatment period, and follow-up period). The daily worst itch score was calculated as the worse of the scores for the 2 questions. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized).
| Percent change | Placebo + TCS | Dupilumab 300 mg Q4W + TCS | Dupilumab 100 mg or 200 mg Q2W + TCS |
|---|---|---|---|
| Percent Change From Baseline in Weekly Average of Daily Worst Itch Score at Week 16 | -25.9 ± 2.90 | -54.6 ± 2.89 | -57.0 ± 2.77 |
The worst itch scale was a simple assessment tool that participants used to report the intensity of their pruritus (itch). This was an 11-point scale (0 to 10) in which 0 indicated no itching while 10 indicated worst itching possible. Participants were asked to answer 2 questions daily throughout the entire study (screening period, treatment period, and follow-up period). The daily worst itch score was calculated as the worse of the scores for the 2 questions. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized). Values after first rescue treatment used were set to missing. Participants with missing score at week 16 were considered as a non-responder. Here "Number of participants analyzed" = number of participants who were evaluated for this specific endpoint.
| Percentage of Participants | Placebo + TCS | Dupilumab 300 mg Q4W + TCS | Dupilumab 100 mg or 200 mg Q2W + TCS |
|---|---|---|---|
| Percentage of Participants With Improvement (Reduction From Baseline) of Weekly Average of Daily Worst Itch Score ≥3 Points at Week 16 | 21.1 | 60.3 | 67.5 |
The worst itch scale was a simple assessment tool that participants used to report the intensity of their pruritus (itch). This was an 11-point scale (0 to 10) in which 0 indicated no itching while 10 indicated worst itching possible. Participants were asked to answer 2 questions daily throughout the entire study (screening period, treatment period, and follow-up period). The daily worst itch score was calculated as the worse of the scores for the 2 questions. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized). Values after first rescue treatment used were set to missing. Participants with missing score at week 16 were considered as a non-responder. Here "Number of participants analyzed" = number of participants who were evaluated for this specific endpoint.
| Percentage of Participants | Placebo + TCS | Dupilumab 300 mg Q4W + TCS | Dupilumab 100 mg or 200 mg Q2W + TCS |
|---|---|---|---|
| Percentage of Participants With Improvement (Reduction From Baseline) of Weekly Average of Daily Worst Itch Score ≥4 Points at Week 16 | 12.3 | 50.8 | 58.3 |
The EASI assessed severity and extent of AD. Scores range from 0-72. Four AD disease characteristics (erythema, thickness, scratching, and lichenification) were assessed for severity on a scale of "0" (absent) through "3" (severe). Area of involvement assessed as a percentage by body area of head, trunk, upper limbs, and lower limbs, and converted to a score of 0 to 6. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized). Values after first rescue treatment used were set to missing. Participants with missing score at week 16 were considered as a non-responder.
| Percentage of Participants | Placebo + TCS | Dupilumab 300 mg Q4W + TCS | Dupilumab 100 mg or 200 mg Q2W + TCS |
|---|---|---|---|
| Percentage of Participants Achieving Eczema Area and Severity Index - 50 (EASI-50) (≥ 50% Improvement From Baseline) at Week 16 | 43.1 | 91.0 | 82.8 |
The EASI assessed the severity and extent of atopic dermatitis (AD). Scores range from 0-72. Four AD disease characteristics (erythema, thickness, scratching, and lichenification) were assessed for severity on a scale of "0" (absent) through "3" (severe). Area of involvement assessed as a percentage by body area of head, trunk, upper limbs, and lower limbs, and converted to a score of 0 to 6. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized). Values after first rescue treatment used were set to missing. Participants with missing score at week 16 were considered as a non-responder.
| Percentage of Participants | Placebo + TCS | Dupilumab 300 mg Q4W + TCS | Dupilumab 100 mg or 200 mg Q2W + TCS |
|---|---|---|---|
| Percentage of Participants Achieving Eczema Area and Severity Index - 90 (EASI - 90) (≥ 90% Improvement From Baseline) at Week 16 | 7.3 | 41.8 | 30.3 |
The worst itch scale: simple assessment tool that participants used to report intensity of their pruritus (itch). This was an 11-point scale (0 to 10) where 0 (no itching) and 10 (worst itching) possible. Participants were asked to answer 2 questions daily throughout the entire study (screening period, treatment period, \& follow-up period). The daily worst itch score was calculated as worse of scores for 2 questions. FAS was used. Time to event is calculated in weeks as (date of first event - date of first dose)/7. The event of NRS reduction ≥ 4 was based on observed data without setting data to be non-responder after rescue treatment use. Here "Number of participants analyzed" = number of participants who were evaluated for this specific endpoint \& "NA" represents "Not computable" as only 12.3% of participants achieved NRS reduction during 16-week treatment period \& hence median time to achieve ≥ 4-point reduction of NRS for placebo +TCS treated participants could not be reported.
| Weeks | Placebo + TCS | Dupilumab 300 mg Q4W + TCS | Dupilumab 100 mg or 200 mg Q2W + TCS |
|---|---|---|---|
| Time to Achieve ≥ 4 Point Reduction of Weekly Average of Daily Worst Itch Score From Baseline During the 16-week Treatment Period | NA (NA to NA) | 10.0 (7 to 13) | 10.0 (8 to 12) |
The worst itch scale: a simple assessment tool that participants used to report intensity of their pruritus (itch). This was an 11-point scale (0 to 10) where 0 (no itching) \& 10 (worst itching) possible. Participants were asked to answer 2 questions daily throughout the entire study (screening period, treatment period, \& follow-up period). Daily worst itch score was calculated as worse of scores for 2 questions. FAS was used. Time to event is calculated in weeks as (date of first event - date of first dose)/7. The event of NRS reduction ≥ 3 was based on observed data without setting data to be non-responder after rescue treatment use. Here "Number of participants analyzed" = number of participants who were evaluated for this specific endpoint \& "NA" represents "Not computable" as only 21.1% of participants achieved NRS reduction during 16-week treatment period \& hence median time to achieve ≥ 3-point reduction of NRS for placebo +TCS treated participants could not be reported.
| Weeks | Placebo + TCS | Dupilumab 300 mg Q4W + TCS | Dupilumab 100 mg or 200 mg Q2W + TCS |
|---|---|---|---|
| Time to Achieve ≥ 3 Point Reduction of Weekly Average of Daily Worst Itch Score From Baseline During the 16-week Treatment Period | NA (11 to NA) | 6.0 (5 to 9) | 5.0 (5 to 7) |
BSA affected by AD was assessed for each section of the body using the rule of nines (the possible highest score for each region is: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]) and were reported as a percentage of all major body sections combined. The proportion assigned to different body regions were different in younger children as compared to older children (head and neck area is assigned a higher proportion in younger children as compared to older children). The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized).
| Percentage of BSA | Placebo + TCS | Dupilumab 300 mg Q4W + TCS | Dupilumab 100 mg or 200 mg Q2W + TCS |
|---|---|---|---|
| Change From Baseline in Percent Body Surface Area (BSA) Affected by Atopic Dermatitis (AD) at Week 16 | -21.65 ± 1.721 | -40.53 ± 1.648 | -39.37 ± 1.629 |
SCORAD was used to assess the extent and severity of AD. Extent and severity of eczema as well as subjective symptoms (insomnia, etc) were assessed and scored. SCORAD total score ranges from 0 (absent disease) to 103 (severe disease). The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized).
| Percent change | Placebo + TCS | Dupilumab 300 mg Q4W + TCS | Dupilumab 100 mg or 200 mg Q2W + TCS |
|---|---|---|---|
| Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) at Week 16 | -29.8 ± 2.26 | -62.4 ± 2.13 | -60.2 ± 2.11 |
CDLQI was a validated 10 question tool to measure the impact of skin disease on the quality of life (QOL) in children by assessing how much the skin problem has affected the participant over the past week. Nine questions were scored as follows: Very much = 3, Quite a lot = 2, Only a little = 1, Not at all or unanswered = 0. Question 7 has an added possible response, which was scored as 3. CDLQI equals the sum of the score of each question (maximum = 30, minimum = 0). Higher the score, the greater the impact on QOL. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized). Data presented reflects the mean \& standard deviation of the CDLQI total scores.
| Score on a Scale | Placebo + TCS | Dupilumab 300 mg Q4W + TCS | Dupilumab 100 mg or 200 mg Q2W + TCS |
|---|---|---|---|
| Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) at Week 16 | -6.4 ± 0.51 | -10.6 ± 0.47 | -10.7 ± 0.46 |
POEM was a 7-item, validated questionnaire used to assess disease symptoms in children and adults. The format was a response to 7 items (dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping) based on frequency of these disease symptoms during the past week (ie, 0 = no days, 1 = 1 to 2 days, 2 = 3 to 4 days, 3 = 5 to 6 days, and 4 = all days) with a scoring system of 0 to 28; the total score reflected the disease-related morbidity. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized). A high score is indicative of a poor quality of life.
| Score on a Scale | Placebo + TCS | Dupilumab 300 mg Q4W + TCS | Dupilumab 100 mg or 200 mg Q2W + TCS |
|---|---|---|---|
| Change From Baseline in Patient Oriented Eczema Measure (POEM) at Week 16 | -5.3 ± 0.69 | -13.6 ± 0.65 | -13.4 ± 0.65 |
The worst itch scale was a simple assessment tool that participants used to report the intensity of their pruritus (itch). This was an 11-point scale (0 to 10) in which 0 indicated no itching while 10 indicated worst itching possible. Participants were asked to answer 2 questions daily throughout the entire study (screening period, treatment period, and follow-up period). The daily worst itch score was calculated as the worse of the scores for the 2 questions. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized).
| Score on a Scale | Placebo + TCS | Dupilumab 300 mg Q4W + TCS | Dupilumab 100 mg or 200 mg Q2W + TCS |
|---|---|---|---|
| Change From Baseline in Weekly Average of Daily Worst Itch Score at Week 16 | -2.05 ± 0.215 | -4.22 ± 0.207 | -4.45 ± 0.206 |
DFI was a 10-item questionnaire with items inquiring about housework, food preparation, sleep, family leisure activity, shopping, expenditure, tiredness, emotional distress, relationships and the impact of helping with treatment on the primary caregiver's life. The DFI questions were scored on a four-point Likert scale ranging from 0 to 3, so that the total DFI score ranges from 0 to 30. Timeframe of reference was the past week. A higher DFI score indicated greater impairment in family Quality of life (QOL) as affected by atopic dermatitis. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized).
| Score on a Scale | Placebo + TCS | Dupilumab 300 mg Q4W + TCS | Dupilumab 100 mg or 200 mg Q2W + TCS |
|---|---|---|---|
| Change From Baseline in Dermatitis Family Index (DFI) at Week 16 | -6.77 ± 0.497 | -10.75 ± 0.476 | -10.89 ± 0.469 |
PROMIS Anxiety instrument measures self-reported fear (fearfulness, panic), anxious misery (worry, dread), hyperarousal (tension, nervousness, restlessness), \& somatic symptoms related to arousal (racing heart, dizziness). Each question has 5 response options ranging in value from 1-5 (1=Never, 2=Almost never, 3=Sometimes, 4=Often, 5=Almost Always). Total raw score calculated using sum of response values: for 8-item form, lowest possible is 8 \& highest possible is 40; For 6-item form: lowest possible is 6; highest possible is 30. Higher score indicates greater severity of symptoms.
| Score on a Scale | Placebo + TCS | Dupilumab 300 mg Q4W + TCS | Dupilumab 100 mg or 200 mg Q2W + TCS |
|---|---|---|---|
| Change From Baseline in Patient Reported Outcomes Measurements Information Systems (PROMIS) Pediatric Anxiety Short Form Scale Total Score at Week 16 | -10.17 ± 0.912 | -13.19 ± 0.861 | -13.54 ± 0.860 |
PROMIS Depression instrument assesses self-reported negative mood (sadness/guilt), views of self (self-criticism/worthlessness) \& social cognition (loneliness/interpersonal alienation), \& decreased positive affect \& engagement (loss of interest/meaning/purpose). Each question has 5 response options with values from 1-5 (1=Never, 2=Almost never, 3=Sometimes, 4=Often, 5=Almost Always). Total raw score is the sum of response values. For 8-item form, lowest possible is 8, highest is 40; for 6-item form, lowest possible is 6, highest is 30. Higher score indicates greater severity of symptoms.
| Score on a Scale | Placebo + TCS | Dupilumab 300 mg Q4W + TCS | Dupilumab 100 mg or 200 mg Q2W + TCS |
|---|---|---|---|
| Change From Baseline in Patient Reported Outcomes Measurements Information Systems (PROMIS) Pediatric Depressive Symptoms Short Form Scale Score at Week 16 | -7.42 ± 0.848 | -12.84 ± 0.793 | -11.92 ± 0.790 |
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) that developed or worsened or became serious during on-treatment period (time from the first dose of study drug up to the end of study. A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-subjects hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs. Percentage of participants having at least one skin infection TEAE (Excluding Herpetic Infections) through Week 16 were reported. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized).
| Percentage of Participants | Placebo + TCS | Dupilumab 300 mg Q4W + TCS | Dupilumab 100 mg or 200 mg Q2W + TCS |
|---|---|---|---|
| Percentage of Participants Having at Least One Skin Infection Treatment Emergent Adverse Event (TEAE) (Excluding Herpetic Infections) Through Week 16 | 13.0 | 5.7 | 8.2 |
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) that developed or worsened or became serious during on-treatment period (time from the first dose of study drug up to the end of study. A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-participants hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized).
| Percentage of Participants | Placebo + TCS | Dupilumab 300 mg Q4W + TCS | Dupilumab 100 mg or 200 mg Q2W + TCS |
|---|---|---|---|
| Percentage of Participants Having at Least One Serious Treatment Emergent Adverse Event (TEAE) Through Week 16 | 1.6 | 1.6 | 0 |
Proportion of TCS medication-free days is calculated as the number of days that a participant used neither TCS/TCI nor system rescue therapy divided by the study days of each period. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized). Here "Number of participants analyzed" = number of participants who were evaluated for this specific endpoint.
| Proportion of Days | Placebo + TCS | Dupilumab 300 mg Q4W + TCS | Dupilumab 100 mg or 200 mg Q2W + TCS |
|---|---|---|---|
| Proportion of Topical Corticosteroid (TCS) Medication-free Days From Baseline to Week 16 | 0.11 ± 0.185 | 0.20 ± 0.230 | 0.19 ± 0.207 |
Mean weekly dose of TCS in grams for low or medium potency TCS from baseline to Week 16 were reported. The FAS included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized). Here "Number of participants analyzed" = number of participants who were evaluated for this specific endpoint.
| Grams | Placebo + TCS | Dupilumab 300 mg Q4W + TCS | Dupilumab 100 mg or 200 mg Q2W + TCS |
|---|---|---|---|
| Mean Weekly Dose of Topical Corticosteroid (TCS) in Grams for Low or Medium Potency TCS From Baseline to Week 16 | 20.1 ± 1.37 | 15.0 ± 1.36 | 14.4 ± 1.38 |
Collected over Reported AEs are treatment-emergent adverse events which were collected for both the 16-week treatment period and the follow-up period for as long as 12 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo + TCS | 0/120 (0%) | 2/120 (1.7%) | 57/120 (47.5%) |
| Dupilumab 300 mg Q4W + TCS | 0/120 (0%) | 3/120 (2.5%) | 47/120 (39.2%) |
| Dupilumab 100 mg or 200 mg Q2W + TCS | 0/122 (0%) | 0/122 (0%) | 50/122 (41%) |
| Event | Placebo + TCS | Dupilumab 300 mg Q4W + TCS | Dupilumab 100 mg or 200 mg Q2W + TCS |
|---|---|---|---|
| Food allergyImmune system disorders | 0/120 | 1/120 | 0/122 |
| Urinary tract infectionInfections and infestations | 0/120 | 1/120 | 0/122 |
| Bone contusionInjury, poisoning and procedural complications | 0/120 | 1/120 | 0/122 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/120 | 0/120 | 0/122 |
| Dermatitis atopicSkin and subcutaneous tissue disorders | 1/120 | 0/120 | 0/122 |
| Event | Placebo + TCS | Dupilumab 300 mg Q4W + TCS | Dupilumab 100 mg or 200 mg Q2W + TCS |
|---|---|---|---|
| Dermatitis atopicSkin and subcutaneous tissue disorders | 17/120 | 8/120 | 10/122 |
| NasopharyngitisInfections and infestations | 8/120 | 15/120 | 8/122 |
| Upper respiratory tract infectionInfections and infestations | 12/120 | 14/120 | 12/122 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 11/120 | 2/120 | 4/122 |
| HeadacheNervous system disorders | 10/120 | 6/120 | 7/122 |
| CoughRespiratory, thoracic and mediastinal disorders | 9/120 | 3/120 | 5/122 |
| VomitingGastrointestinal disorders | 8/120 | 6/120 | 6/122 |
| Injection site erythemaGeneral disorders | 2/120 | 5/120 | 7/122 |
| ConjunctivitisInfections and infestations | 3/120 | 5/120 | 7/122 |
| Viral upper respiratory tract infectionInfections and infestations | 6/120 | 2/120 | 1/122 |
The full analysis set (FAS) includes all randomized participants.
| Age, Continuous(years) | Placebo + TCS | Dupilumab 300 mg Q4W + TCS | Dupilumab 100 mg or 200 mg Q2W + TCS | Total |
|---|---|---|---|---|
| Mean | 8.3 ± 1.76 | 8.5 ± 1.74 | 8.5 ± 1.68 | 8.5 ± 1.72 |
| Sex: Female, Male(Participants) | Placebo + TCS | Dupilumab 300 mg Q4W + TCS | Dupilumab 100 mg or 200 mg Q2W + TCS | Total |
|---|---|---|---|---|
| Female | 62 | 65 | 57 | 184 |
| Male | 61 | 57 | 65 | 183 |
| Ethnicity (NIH/OMB)(Participants) | Placebo + TCS | Dupilumab 300 mg Q4W + TCS | Dupilumab 100 mg or 200 mg Q2W + TCS | Total |
|---|---|---|---|---|
| Hispanic or Latino | 13 | 16 | 16 | 45 |
| Not Hispanic or Latino | 110 | 106 | 106 | 322 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo + TCS | Dupilumab 300 mg Q4W + TCS | Dupilumab 100 mg or 200 mg Q2W + TCS | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 13 | 5 | 10 | 28 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 23 | 19 | 20 | 62 |
| White | 77 | 89 | 88 | 254 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 10 | 9 | 4 | 23 |
| Eczema Area and Severity Index (EASI) Score(Score on a Scale) | Placebo + TCS | Dupilumab 300 mg Q4W + TCS | Dupilumab 100 mg or 200 mg Q2W + TCS | Total |
|---|---|---|---|---|
| Mean | 39.0 ± 12.01 | 37.4 ± 12.45 | 37.3 ± 10.86 | 37.9 ± 11.79 |
| Investigator's Global Assessment (IGA) Score(Score on a Scale) | Placebo + TCS | Dupilumab 300 mg Q4W + TCS | Dupilumab 100 mg or 200 mg Q2W + TCS | Total |
|---|---|---|---|---|
| Mean | 4.0 ± 0.00 | 4.0 ± 0.09 | 4.0 ± 0.00 | 4.0 ± 0.05 |
| Weekly Average of Daily Worst Itch Score(Score on a Scale) | Placebo + TCS | Dupilumab 300 mg Q4W + TCS | Dupilumab 100 mg or 200 mg Q2W + TCS | Total |
|---|---|---|---|---|
| Mean | 7.7 ± 1.54 | 7.8 ± 1.58 | 7.8 ± 1.52 | 7.8 ± 1.54 |
| Body Surface Area (BSA) of Atopic Dermatitis(Percentage of BSA) | Placebo + TCS | Dupilumab 300 mg Q4W + TCS | Dupilumab 100 mg or 200 mg Q2W + TCS | Total |
|---|---|---|---|---|
| Mean | 60.2 ± 21.46 | 54.8 ± 21.58 | 57.8 ± 20.04 | 57.6 ± 21.10 |
6 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2017 to primary completion in Jun 2019, 19 months.
Results were first posted in Aug 2020, 1 year 1 month after primary completion.
Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 19 months is close to that.
Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dupilumab